delayed-release

On April 30, 2010, the Company announced that the U.S. Food and Drug Administration (FDA) approved VIMOVO delayed-release tablets for the relief of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

unknown title 2011

First half sales of VIMOVO™ naproxen / esomeprazole magnesium delayed-release tablets were $10.1 million; $6.3 million in Q2 2011.

unknown title 2011

VIMOVO® naproxen/esomeprazole magnesium 375/20-500/20 mg delayed-release tablets, which is a prescription-strength pain reliever that can help patients avoid stomach issues common to NSAIDs.

unknown title 2011

VIMOVO™ (naproxen / esomeprazole magnesium) delayed-release tablets, co-developed by POZEN Inc. and AstraZeneca, is a fixed-dose combination of delayed-release enteric-coated naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID), and immediate release esomeprazole, a proton pump inhibitor (PPI).

unknown title 2011

VIMOVO is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

unknown title 2011

On October 8, 2010, the U.S. Food and Drug Administration ("FDA") approved ATELVIA (risedronate sodium) delayed-release tablets, our next generation ACTONEL product, for the treatment of postmenopausal osteoporosis in the United States.

unknown title 2011

First half sales of VIMOVO™ naproxen / esomeprazole magnesium delayed-release tablets were $10.1 million; $6.3 million in Q2 2011.

unknown title 2011

VIMOVO™ (naproxen / esomeprazole magnesium) delayed-release tablets, co-developed by POZEN Inc. and AstraZeneca, is a fixed-dose combination of delayed-release enteric-coated naproxen, a pain-relieving non-steroidal anti-inflammatory drug (NSAID), and immediate release esomeprazole, a proton pump inhibitor (PPI).

unknown title 2011

On April 30, 2010, the Company announced that the U.S. Food and Drug Administration (FDA) approved VIMOVO delayed-release tablets for the relief of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.

unknown title 2011

For some background, on June 6, the company announced that on June 3 the last clinical trial patient visits were completed and final data analysis will commence this week on the Phase 3 clinical trial of its delayed-release oral formulation of DR Cysteamine in patients with cystinosis.

unknown title 2011